Reps will tout new evidence that Fosamax increases bone density better than Actonel

December 2004

Reps will tout new evidence that Fosamax increases bone density better than Actonel in postmenopausal women.

But this is only part of the story.

It's true that a new study suggests Fosamax (alendronate) increases bone density of the hip by 3.4% in one year... compared to only 2.1% for Actonel (risedronate).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote